Addition of a macrolide to a β-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia

Clinical Infectious Diseases

Volumn 36, Issue 4, 2003, Pages 389-395

  Martínez, José A ^a   Horcajada, Juan P ^a   Almela, Manuel ^a   Marco, Francesc ^a   Soriano, Alex ^a   García, Elisa ^a   Marco, Maria Angeles ^a   Torres, Antoni ^a   Mensa, Josep ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CARBAPENEM; CEFEPIME; CEFOTAXIME; CEFTRIAXONE; CIPROFLOXACIN; CLARITHROMYCIN; CLINDAMYCIN; CLOXACILLIN; COTRIMOXAZOLE; ERYTHROMYCIN; MACROLIDE; PENICILLIN DERIVATIVE; RIFAMPICIN; VANCOMYCIN;

ADULT; AGE; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTEREMIA; BACTERIAL PNEUMONIA; COMORBIDITY; CONTROLLED STUDY; DATA BASE; FEMALE; FOLLOW UP; HUMAN; LOBAR PNEUMONIA; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; SHOCK; STREPTOCOCCUS PNEUMONIAE;

ANTI-BACTERIAL AGENTS; BACTEREMIA; BETA-LACTAMS; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MACROLIDES; MALE; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PNEUMONIA, PNEUMOCOCCAL; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 0037442372     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/367541     Document Type: Article

References (18)

1. Mufson MA, Stanek RJ. Bacteremic pneumococcal pneumonia in one American city: a 20-year longitudinal study, 1978-1997. Am J Med 1999; 107(Suppl 1A):34S-43S.
2. Stahl JE, Barza M, DesJardin J, Martin R, Eckman MH. Effect of macrolides as part of initial empiric therapy on length of stay in patients hospitalized with community-acquired pneumonia. Arch Intern Med 1999; 159:2576-80.
3. Gleason PP, Meehan TP, Fine JM, Galusha DH, Fine MJ. Association between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia. Arch Intern Med 1999; 159:2562-72.
4. Dudas V, Hopefl A, Jacobs R, Guglielmo BJ. Antimicrobial selection for hospitalized patients with presumed community-acquired pneumonia: a survey of nonteaching US community hospitals. Ann Pharmacother 2000; 34:446-52.
5. Waterer GW, Somes GW, Wunderink RG. Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia. Arch Intern Med 2001; 161:1837-42.
6. Bartlett JG, Dowell SF, Mandell LA, File TM, Musher DM, Fine MJ. Practice guidelines for the management of community-acquired pneumonia in adults. Clin Infect Dis 2000; 31:347-82.
7. Houck PM, MacLehose RF, Niederman MS, Lowery JK. Empiric antibiotic therapy and mortality among Medicare pneumonia inpatients in 10 western states. Chest 2001; 119:1420-6.
8. Ruiz-González A, Falguera M, Nogués A, Rubio-Caballero M. Is Streptococcus pneumoniae the leading cause of pneumonia of unknown etiology? A microbiologic study of lung aspirates in consecutive patients with community-acquired pneumonia. Am J Med 1999; 106:385-90.
9. Johansen HK, Jensen TG, Dessau RB, Lundgren B, Frimodt-Moller N. Antagonism between penicillin and erythromycin against Streptococcus pneumoniae in vitro and in vivo. J Antimicrob Chemother 2000; 46:973-80.
10. National Committee for Clinical Laboratory Standards (NCCLS). Performance standards for antimicrobial susceptibility testing, 12th international supplement. NCCLS document M100-S12 Wayne, PA: NCCLS, 2002.
11. McCabe WR, Jackson GG. Gram-negative bacteremia. I. Etiology and ecology. Arch Intern Med 1962; 110:847-55.
12. Torres A, Serra-Batlles J, Ferrer A, et al. Severe community-acquired pneumonia: epidemiology and prognostic factors. Am Rev Respir Dis 1991; 144:312-9.
13. Pachon J, Prados MD, Capote F, Cuello JA, Garnacho J, Verano A. Severe community-acquired pneumonia: etiology, prognosis, and treatment. Am Rev Respir Dis 1990; 142:369-73.
14. Marston BJ, Plouffe JF, File TM, et al. Incidence of community-acquired pneumonia requiring hospitalization: results of a population-based active surveillance study in Ohio. Arch Intern Med 1997; 157:1709-18.
15. Kauppinen MT, Saikku P, Kujala P, Herva E, Syrjälä H. Clinical picture of community-acquired Chlamydia pneumoniae pneumonia requiring hospital treatment: a comparison between chlamydial and pneumococcal pneumonia. Thorax 1996; 51:185-9.
16. Mundy LM, Oldach D, Auwaerter PG, et al. Implications for macrolide treatment in community-acquired pneumonia. Chest 1998; 113:1201-6.
17. Azoulay-Dupuis E, Rieux V, Muffat-Joly M, et al. Relationship between capsular type, penicillin susceptibility and virulence of human Streptococcus pneumoniae isolates in mice. Antimicrob Agents Chemother 2000; 44:1575-7.
18. Hoyt JC, Robbins RA. Macrolide antibiotics and pulmonary inflammation. FEMS Microbiol Lett 2001; 205:1-7.